Table 2.
Pathology Findings in Patients with Differentiated Thyroid Cancer
| DTC cases | Mean ± SD % CD11b+MDSC | Fraction with >12% CD11b+MDSC (%) | |
|---|---|---|---|
| Recurrent DTC | 3/35 (8.6) | 23.2 ± 8.1 | 3/3 (100) |
| Primary DTC | 32/35 (91.4) | 13.9 ± 6.1 | 23/32 (71.9) |
| Tumor size | |||
| <1 cm | 8 (25.0) | 11.0 ± 5.4 | 5/8 (62.5) |
| >1 cm | 24 (75.0) | 14.9 ± 6.1 | 19/24 (79.2) |
| Invasion | |||
| Encapsulated | 15 (46.9) | 12.5 ± 6.5 | 9/15 (60.0) |
| Invasivea | 17 (53.1) | 15.2 ± 5.7 | 14/17 (82.4) |
| Nodes | |||
| Nx,N0 | 20 (62.5) | 13.6 ± 6.7 | 13/20 (65.0) |
| N1b | 12 (37.5) | 14.6 ± 5.2 | 10/12 (83.3) |
| Distant metastasis at presentation | |||
| No | 30 (94.3) | 14.0 ± 6.3 | 21/30 (70.0) |
| Yesc | 2 (5.7) | 13.3 ± 0.2 | 2/2 (100) |
| AJCC TNM stage | |||
| I–II | 19 (59.4) | 12.4 ± 6.6 | 8/19 (50.0) |
| III | 8 (25.0) | 16.0 ± 4.6 | 6/8 (75.0) |
| IV | 5 (15.6) | 16.1 ± 2.1 | 5/5 (100) |
| ATA risk | |||
| Low | 11 (37.4) | 12.6 ± 7.1 | 6/11 (54.5) |
| Int | 14 (43.8) | 13.1 ± 6.1 | 9/14 (64.3) |
| High | 7 (21.8) | 16.6 ± 3.8 | 7/7 (100) |
| MACIS score | |||
| <6 | 15 (46.9) | 10.9 ± 5.3 | 7/15 (46.7) |
| 6–7 | 8 (25.0) | 15.2 ± 7.7 | 6/8 (75.0) |
| >7 | 9 (28.1) | 16.9 ± 3.7 | 9/9 (100) |
| Response to treatment | |||
| No evidence of disease | 13.2 ± 6.8 | 13/21 (62.0) | |
| Persistent disease | 19.4 ± 5.4 | 6/6 (100) | |
a
Includes lymphovascular invasion, and extracapsular and/or extrathyroidal extension.
b
Includes central neck (N1a) and/or lateral neck (N1b).
c
Two patients with lung metastasis at presentation.
AJCC TNM, American Joint Committee on Cancer Tumor-Nodal-Metastasis staging; ATA, American Thyroid Association; MACIS, distant Metastasis, Age, Completeness of resection, local Invasion, and tumor Size.